杂志简称：digestion
中文译名：《消化》
收录属性：高质量科技期刊（t3）, scie（2024版）, 目次收录（维普）,英文期刊,
自引率：14.00%
投稿方向：医学、gastroenterology & hepatology 胃肠肝病学
SCI/E期刊基本信息
出版周期：双月刊 地区：瑞士
中科院分区：3区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：非OA期刊
国际标准刊号：ISSN0012-2823；EISSN1421-9867
杂志语言：英语
出版国家：瑞士
杂志官网 联系方式
出版地址：KARGER,ALLSCHWILERSTRASSE 10,BASEL,SWITZERLAND,CH-4009
杂志邮箱：
投稿网址：https://www.manuscriptmanager.net/DIG?product-id=223838
杂志官方网址：http://www.karger.com/Journal/Home/223838
出版商网址：http://www.karger.ch
杂志投稿要求
投稿须知【杂志社官方网站信息】
Digestion
Author Guidelines
About the Journal
Aims and Scope
Digestion concentrates on clinical research reports: in addition to editorials and reviews, the journal features sections on stomach/esophagus, bowel, neurogastroenterology, liver/bile, pancreas, metabolism/nutrition, and gastrointestinal oncology. Papers cover physiology in humans, metabolic studies, and clinical work on the etiology, diagnosis, and therapy of human diseases. It is thus especially cut out for gastroenterologists employed in hospitals and outpatient units. Moreover, the journal’s coverage of studies on the metabolism and effects of therapeutic drugs carries considerable value for clinicians and investigators beyond the immediate field of gastroenterology.
Journal Sections
To The Point Articles
Digestion publishes a series of solicited mini-reviews aimed at giving a short, up-to-date, and to the point overview of a specific pathology or treatment. The article provide physicians and researchers with a description of the current treatment standards, the most important discoveries of the last 12 months from a clinical and basic research point of view, and an outlook for the near future.
To The Point Articles should be submitted upon invitation only. Authors planning to submit an unsolicited paper are requested to contact the Editorial Office with an outline of the intended contribution. Articles should not exceed 1,750 words, divided into head-lined paragraphs and including up to 5 Key Points that summarize the main conclusions of the article (max. 20 words each). The title may be up to 15 words. The abstract may be up to 250 words and should include the Key Messages. Authors may include 1-2 tables or illustrations and a maximum of 25 references.
Article Types
Research Article
Research Articles report on primary research. They must describe significant and original observations. Consideration for publication is based on the article’s originality, novelty, and scientific soundness, and the appropriateness of its analysis.
Research Articles are reports of original work. Authors are asked to follow the EQUATOR Network for Research Articles.
Prior approval from an Institutional Review Board (IRB) or an Ethics Review Committee is required for all investigations involving human subjects.
A downloadable template is available below.
Documents
Research Article (DOCX, 28.97 KB)
Review Article
Review Articles are considered reviews of research or summary articles. They are state-of-the-art papers covering a current topic by experts in the field. They should give evidence on and provide answers to a well-defined aspect or question in a particular area. Review Articles must include a critical discussion of the reported data and give a clear conclusion with potential impacts on the standard of care.
A downloadable template is available below.
Documents
Review Article (DOCX, 23.66 KB)
Reviews should contain a maximum of 4,000 words, except for invited "To the Point" articles (see Journal Sections for more information).
Brief Report
Brief Reports are short and/or rapid announcements of research results. They must contain data derived from cutting-edge research and be of potential interest to a large proportion of the readership. They are independent, concise reports representing a significant contribution to the field. Such communications should represent complete, original studies and should be arranged in the same way as full-length manuscripts with subheadings.
A downloadable template is available below.
Documents
Brief Report (DOCX, 27.12 KB)
Editorial
Editorials provide a viewpoint on specific articles or on general subjects directly relevant to the journal. Editorials are written by an editor or other member of the journal.
Editorials should not exceed 500 words
A downloadable template is available below.
Documents
Editorial (DOCX, 24.95 KB)
Meeting Report/Abstract
A downloadable template is available below.
Documents
Meeting Report (DOCX, 22.5 KB)
Authors should contact the Editor-in-Chief before submitting a Meeting Report.
Contact Information
Should you have any problems with your submission, please contact the editorial office:
Simon Turner
Editorial Office 'Digestion'
S. Karger AG
P.O. Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1358
Fax +41 61 306 1434
dig@karger.com
Editorial and Journal Policies
General Conditions
Only papers written in English are considered. The articles should be comprehensible to a reader who is fluent in English and should be edited prior to submission to ensure that standard English grammar and usage are observed. Use of a professional language editing service prior to submission can help avoid delays with the review process.
All manuscripts are subject to editorial review.
The presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals from the International Committee of Medical Journal Editors (ICMJE).
Karger journals aim to adhere to the COPE Code of Conduct and Best Practice Guidelines.
By submitting an article for publication, the authors agree to the transfer of the copyright to the publisher upon acceptance. Accepted papers become the permanent property of the Journal and may not be reproduced by any means, in whole or in part, without the written consent of the publisher.
The Submission Statement with original (hand-written) signatures is to be provided upon submitting the paper. If it is not possible to collect all signatures on a single document, individual copies should be provided for each author.
Karger recommends the use of original images and materials whenever possible. If a submitted manuscript contains third-party copyright material(s), it is the authors’ sole responsibility to obtain permission from the relevant copyright holder for reusing the material(s), including any associated licensing fee. The copyright and usage information needs to be checked carefully to avoid copyright infringement.
Most publishers offer a quick and easy way to clear permissions for their content via the built-in website application RightsLink or via https://www.copyright.com/get-permissions/. Another widely used licensing tool is PLSClear. Please check the publishers’ websites for the available options and user instructions.
Statements
All submitted manuscripts must contain a Statement of Ethics, a Conflict of Interest Statement, an Author Contributions Statement and a Data Availability Statement after the main body of the text, but before the reference list.
Statement of Ethics
Published research must comply with internationally-accepted standards for research practice and reporting. Manuscripts may be rejected if the editors believe that the research has not been carried out within an appropriate ethical framework, and concerns raised after publication may lead to a correction, retraction, or expression of concern in line with COPE guidelines.
Studies involving human subjects (including research on identifiable human material and data) must have been performed with the approval of an appropriate ethics committee and with appropriate participants’ informed consent in compliance with the Helsinki Declaration.
In the manuscript, authors should specify the name of the ethics committee or other relevant authority who approved the study protocol and provide the reference number where appropriate. If ethics approval was not required, or if the study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee who made that decision).
For all research involving human subjects, written informed consent to participate in the study should be obtained from participants (or their parent/legal guardian where appropriate ) and a statement detailing this should appear in the manuscript. For studies involving vulnerable participants or participants at risk of potential coercion, detailed information regarding the steps taken to ensure informed consent must be provided. If consent was not obtained, please specify why and whether this was approved by the ethics committee.
In line with the ICMJE recommendations on the protection of research participants, authors must avoid providing identifying information unless strictly necessary for the submission and participants’ identifiable attributes must be anonymized in the manuscript and its supplementary files, if any. If identifying information is necessary, authors must confirm that the individual has provided written consent for the use of that information in a publication.
Research involving human embryonic stem cells, embryonic germ cells or induced pluripotent stem cells should comply with the ISSCR 'Guidelines for the Conduct of Human Embryonic Stem Cell Research' or an equivalent set of guidelines or applicable regulations.
Case Reports: Manuscripts reporting a case report must include a statement detailing that written informed consent for publication was obtained and from whom (e.g. “Written informed consent was obtained from the patient for publication of this case report and any accompanying images.”). If the patient has died, consent for publication must be obtained from their next of kin. If the patient described in the case report is a minor or vulnerable, then consent for publication must be obtained from the parent/legal guardian. The completed consent form must be made available to the Editor if requested, and will be treated confidentially.
Clinical Trials: In accordance with the ICMJE recommendations, all clinical trials should be registered in a publicly available registry approved by the WHO or ICMJE (see the list here) and the clinical trial number must be clearly stated in the manuscript. Manuscripts reporting clinical trials must adhere to the relevant reporting guidelines for their study design, such as CONSORT for randomized controlled trials, TREND for non-randomized trials, or other relevant reporting guidelines as detailed on the Equator network website.
Karger follows the WHO definition of clinical trials "A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes […] Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc. This definition includes Phase I to Phase IV trials.”
Studies involving animals: Experimental research on vertebrates or any regulated invertebrates must have been approved by the authors' Institutional Animal Care and Use Committee (IACUC) or equivalent ethics committee and must follow internationally recognized guidelines such as the ARRIVE guidelines. In the manuscript, authors should specify the name of the ethics committee or other relevant authority who approved the study protocol and provide the reference number where appropriate.
If ethics approval was not required, or if the study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee who made that decision). Additional information is expected for studies reporting death of a regulated animal as a likely outcome or planned endpoint. Other types of studies including field studies and non-experimental research on animals must comply with local or international guidelines, and where appropriate must have been approved by an appropriate ethics committee.
Conflict of Interest Statement
Karger endorses the ICMJE recommendations on the ‘Disclosure of Financial and Non-Financial Relationships and Activities, and Conflicts of Interest’. Authors are required to disclose any relationship that could reasonably be perceived by a reader as a potential conflict of interest at the time of submission. All forms of support and financial involvement (e.g. employment, consultancies, honoraria, stock ownership and options, expert testimony, grants or patents received or pending, royalties) which took place in the previous three years should be listed, regardless of their potential relevance to the paper. Also the nonfinancial relationships (personal, political, or professional) that may potentially influence the writing of the manuscript should be declared. The role of the funder in study design; collection, analysis, and interpretation of data; writing of the report; any restrictions regarding the submission of the report for publication should be declared. If the funder had no role in any of the above, this should be clearly stated in the manuscript’s funding section.
Author Contributions Statement
In the Author Contributions section, a short statement detailing the contributions of each person named as an author should be included. Contributors to the paper who do not fulfill the ICMJE Criteria for Authorship should be credited in the Acknowledgement section. If an author is removed from or added to the listed authors after submission, an explanation and a signed statement of agreement confirming the requested change are required from all the initially listed authors and from the author to be removed or added.
Data Availability Statement
The journal’s data sharing policy strongly encourages authors to make all datasets on which the conclusions of the paper rely available to editors, reviewers and readers without unnecessary restriction wherever possible. Authors are required to provide a Data Availability Statement in their article that details whether data are available and where they can be found. In cases where research data are not publicly available on legal or ethical grounds, this should be clearly stated in the Data Availability Statement along with any conditions for accessing the data. The decision to publish will not be affected by whether or not authors share their research data.
Examples of Data Availability statements:
· The data that support the findings of this study are openly available in [repository name e.g “figshare”] at http://doi.org/[doi], reference number [reference number]
· Publicly available datasets were used in this study. These can be found in [repository name e.g “figshare”] at http://doi.org/[doi], reference number [reference number]
· All data generated or analyzed during this study are included in this article [and/or] its supplementary material files. Further enquiries can be directed to the corresponding author.
· The data that support the findings of this study are not publicly available due to [REASON WHY DATA ARE NOT PUBLIC e.g. their containing information that could compromise the privacy of research participants] but are available from [e.g. the corresponding author [author initials] OR Data sharing committee [PROVIDE CONTACT DETAILS including email address] upon reasonable request]
· The data in this study was obtained from [third party source] where [RESTRICTIONS/LICENCE] may apply. Such dataset may be requested from [source contact information].
Please note if authors are submitting to a journal with a double blind peer review policy, the data availability statement should be anonymized where appropriate.
Definition of research data: This policy applies to the research data that would be required to verify the results of research reported in articles published in the journal. Research data include data produced by the authors (“primary data”) and data from other sources that are analysed by authors in their study (“secondary data”). Research data includes any recorded factual material that are used to produce the results in digital and non-digital form. This includes, but is not limited to, tabular data, code, images, audio, documents, video, maps, raw and/or processed data.
For images, Karger requests that individual/unique features within an image are not modified, and image-processing methods do not alter the original image information ( the use of software and/or enhancement technique must be disclosed in the methods section). Any concerns raised over inappropriate image modification will be investigated in accordance with COPE guidelines.
Policy exceptions: This policy does not require public sharing of quantitative or qualitative data that could identify a research participant unless participants have consented to data release. The policy also does not require public sharing of other sensitive data, such as the locations of endangered species. Alternatives to public sharing of sensitive or personal data include:
● Depositing research data in controlled access repositories
● Anonymizing or deidentifying data before public sharing
● Only sharing metadata about the research data
● Stating the procedures for accessing your research data in the article and managing data access requests from other researchers
Embargoes: Embargoes on data sharing are permitted but should be clearly stated in the data availability statement, including the reason for embargo, date of the end of the embargo period and how and where the data can be accessed following the end of the embargo period. Please note that all datasets on which the conclusions of the paper rely must be made available to editors and reviewers if requested to facilitate the review process.
Data repositories: The preferred mechanism for sharing research data is via public data repositories. We encourage authors to select a data repository that issues a persistent identifier, preferably a Digital Object Identifier (DOI), and has established a robust preservation plan to ensure the data is preserved in perpetuity. Additionally, we highly encourage researchers to consider the FAIR Data Principles when depositing data. Authors are encouraged to deposit their research data in a repository that has been widely adopted within their research community, suitable repositories per each area and data type can be searched using the FAIRsharing database tool (https://fairsharing.org/databases/) or via https://repositoryfinder.datacite.org.
If no such database is available authors may use a general data repository. Examples of general data repositories include:
· Figshare (www.figshare.com)
· Dryad (www.datadryad.org)
· Zenodo (www.zenodo.org)
· Open Science Framework (https://osf.io/)
If authors are submitting an article to a journal with a double blind peer review policy, they should deposit their data in a repository that allows them to temporarily preserve anonymity such as Figshare (“private sharing link”) or Dryad (“private for peer review”).
Data citation: The journal encourages authors to cite any publicly available research data in their reference list. References to datasets (data citations) must include a persistent identifier (such as a DOI). Citations of datasets, when they appear in the reference list, should include the minimum information recommended by DataCite (e.g. author(s), title, publisher (repository name), DOI) and follow journal style.
Data licensing: The journal encourages research data to be made available under open licences that permit reuse freely. The journal does not enforce particular licenses for research data, where research data are deposited in third party repositories. The publisher of the journal does not claim copyright for research data.
Reference: Hrynaszkiewicz, I, Simons, N, Hussain, A, Grant, R and Goudie, S. 2020. Developing a Research Data Policy Framework for All Journals and Publishers. Data Science Journal, DOI: http://doi.org/10.5334/dsj-2020-005.